Jim Cramer observed the struggling performance of
Haleon, which updated its
share capital and
voting rights total. Forward speculation hints at a possible recovery for Haleon, with signs of stock brightening amid favourable market trends. Despite near-term hurdles, Haleon's
brands demonstrate long-term promise and receive an average rating of "
Moderate Buy" from brokerages. However, growth seems to be fairly limited. Notably,
Bain Capital sold 430,104 Haleon shares while
Barclays downgraded Haleon due to growth concerns. Surprisingly,
New York State Retirement Fund made an investment in Haleon, sparking potential growth acceleration. Despite a revenue forecast cut, Haleon saw a
share price jump following on from a Morgan Stanley “Top Pick” call and board changes. Other investors such as
Quantbot Technologies LP also acquired Haleon shares. Haleon's net voting rights and share capital amount to
8.91 billion shares. In response to North America's weak demand, Haleon adjusted its organic revenue growth outlook. Pfizer made a notable exit, selling their final Haleon stake for $3.2B. Haleon’s stock performance fluctuated but concluded with Q3 results showing volume growth improvement.
Haleon Stocks News Analytics from Thu, 27 Feb 2025 08:00:00 GMT to Sat, 03 Jan 2026 08:04:01 GMT -
Rating 1
- Innovation 0
- Information 6
- Rumor -5
